Phenoxy-hydroxypropylamines, method and pharmaceutical preparations for treating cardiovascular diseases

ABSTRACT

Para-substituted phenoxy-hydroxypropylamines having the general formula   And pharmaceutically acceptible, non-toxic acid addition salts thereof, wherein R is an isopropyl or tertiarybutyl radical; Z is a member selected from the group consisting of --OR&#34;, --SR&#34;, and --NHCOOR&#34;, R&#34; being a straight or branched lower alkyl radical having 1 to 3 carbon atoms; and n is 1, 2, or 3, are disclosed as are methods for their preparation. Pharmaceutical preparations are prepared whose active ingredients include at least one of the newly discovered phenoxy-hydroxypropylamine compounds. Therapeutically effective does of these preparations selectively block the .beta.-receptors of the heart marking them useful in treating heart diseases in animals including humans.

United States Patent n91 Br'zindstriim et al.

[541 PIIENoXYJIYDROXYPRoPYLAMINEs,

METHOD AND PHARMACEUTICAL PREPARATIONS FOR TREATING CARDIOVASCULAR DISEASES [22] Filed: Jan. 15, I974 [2]] Appl. No.: 433,565

Related U.S. Application Data [60] Division of Ser. No. 342,749, March 19, 1973, abandoned, which is a continuation-in-part of Ser. No. 115,85l. Feb. I6, I97], abandoned.

[52] U.S. Cl. 424/330 [51] Int. Cl A6lk 27/00 [58] Field of Search 424/330; 260/47] C [56] References Cited UNITED STATES PATENTS 3,637,827 l/l972 Kaiser et al. 260/471 C Apr. 8, 1975 Primary E.\'anIiner Stanley J. Friedman Attorney, Agent, or Firm-Brambaugh, Graves, Donohue & Raymond [57] ABSTRACT Para-substituted phenoxy-hydroxypropylamines having the general formula and pharmaceutically acceptible, non-toxic acid addition salts thereof, wherein R is an isopropyl or tertiarybutyl radical; Z is a member selected from the group consisting of OR", SR", and NH- COOR", R" being a straight or branched lower alkyl radical having l to 3 carbon atoms; and n is l, 2, or 3, are disclosed as are methods for their preparation. Pharmaceutical preparations are prepared whose active ingredients include at least one of the newly discovered phenoxy-hydroxypropylamine compounds. Therapeutically effective does of these preparations selectively block the B-rcceptors of the heart marking them useful in treating heart diseases in animals including humans.

23 Glaims, No Drawings 1, PIIENOXY-IIYDROXYPROPYLAMINES, METHOD AND PHARMACEUTICAL PREPARATIONS FOR TREATING CARDIOVASCULAR DISEASES This is a division of Ser. No. 342,749 filed Mar. 19, 1973, now abandoned which is a continuation-in-part of our copending application Ser. No. 115,851 filed Feb. 16, 1971 now abandoned.

The present invention relates to phenoxyhydroxypropylamines and, in particular, to parasubstituted phenoxy-hydroxypropylamines and methods for their preparation. The invention also relates to the preparation of pharmaceutical preparations containing such para-substituted phenoxyhydroxypropylamines as active ingredients and to a method for the pharmacological use of such compounds.

B-Receptor blocking agent such as propranolol,

CH -CH-CH -NHCH CH 2 o-ca -cihca have been shown to possess good therapeutic effects in treating heart diseases and vascular diseases, such as angina pectoris, hypertension, vasoregulatoric neurasteni and certain forms of arrythmia.

Certain disadvantages have been experienced in the therapeutic use of these compounds since they block not only the B-receptors of the heart, which leads to the therapeutic effect, but also the B-receptors in blood vessels and bronchi. The latter blocking activity results in undesired side effects with some patients having manifest or latent asthma. Blocking of the ,B-receptors in the bronchi may in such cases lead to broncho-spasm and attacks of asthma. For this reason, asthma is a contraindication for heart disease treatment with the known ,B-receptor-blocking substances such as propanolol, alprenolol, and oxprenolol. The receptor blocking effect on blood vessels of these compounds causes adrenaline, which is released from the marrow of the superarenal glands, to have a pure pressor effect instead of the balanced pressor-depressor effect normally maintained by adrenaline flow.

Accordingly, the main object of the invention is to provide new para-substituted phenoxyhydroxypropylamine compounds having variable pharmacological properties which can be used in the treatment of heart diseases.

Another object of this invention is to provide new compounds which have a therapeutic effect in treating heart diseases without inducin complications due to B-blockade in bronchi and in blood vessels.

These and other closely related purposes of the present invention are achieved by administering parasubstituted phenoxyhydroxypropylamine derivatives characterized by the following general formula:

and pharmaceutically acceptable, non-toxic acid addition salts thereof, wherein R is an isopropyl or tertiarybutyl radical; Z is a member selected from the group consisting essentially of OR", --SR", and NH-- l-isopropylamino 3-[p-(ethoxymethyl)-phenoxy]- pr0panol-2; l-isoprop ylamino-3- p-( 'ymethoxypropyl )-phenoxy -propanol-2; 1-

- isopropylamino-3j-[p-(B-methylmercaptoethyl)- phenoxy]-propanol-2; and l-isopropylamino-3-[p-( B- methoxycarbonylamidoethyl)-phenoxy]-propanol-2.

1-lsopropylamino-3-[p-(B-methoxyethyl)-phenoxy]- propanol-2 and l-isopropylamino-3-[p-(B- methoxycarbonylamidoethyl)-phenoxy]-propanol-2 are preferred both as racemates as well as in the form of their phannacologically and optically active isomers.

The para-substituted phenoxy-hydroxypropylamines of Formula IV may be prepared by several methods which are defined as follows:

A. Reacting a compound of the formula (CH2) Z with a compound of the formula in which formulas R is an isopropyl or tertiary-butyl radical; Z is a member selected from the group consisting of --OR", SR", and NHCOOR, R" being a straight or branched lower alkyl radical having l. to 3 carbon atoms; and n is 1, 2, or 3. Q in Formula V repre- SCIltS or CHOHCH X, wherein X is a halogen atom, preferably chlorine.

B. Reacting a compound of Formula V with an amine of the formula H N--R wherein n, Z, R, and Q have the same meaning designated above in (A).

C. Alkylating a compound of the formula (VII) (CH Z in which formulas n, and Z have the same meaning as designated in (A).

D. Alkylating a compound of the formula (CH Z by reacting it with a compound of the formula X- CH-[CH to form compounds of formula VI", wherein n, Z, R, and X have the same meaning as designated in (A).

E. Hydrolysis of a compound of the formula CH -(l3H-CH -NH-R' wherein n, Z, and R have the same meaning as in (A) and R is a group which can be removed hydrolytically, preferably an acyl or a tetrahydropyranyl group.

F. Hydrolysis of a compound of the formula using a strong alkali or strong acid, wherein n, Z, and R have the same meaning as in (A).

G. Hydrolysis or pyrolysis of a compound of the formula t (H R (XII) wherein n, Z,-and R have the same meaning as above and R and R each represents a hydrogen atoms, a lower alkyl, aralkyl, or aryl group.

H. Hydrolysis or hydrogenolysis of a compound of the formula (XIII) (XIV) with a compound of the formula Q-CH NHR' in which formulas n, Z, R, and Q have the same meaning as in A and M is a cation, preferably an alkali metal cation.

J. Reducing a compound of the formula (CH Z preferably by using a complex alkali metal hydride, wherein n, Z, and R have the same meaning as in (A) and Y represents CHOHCO- or COCH K. Hydrolysis of a compound of the formula (CH Z wherein n, Z, and R have the same meaning as in (A), and R is a lower alkyl, aralkyl, or aryl group, preferably a phenyl group.

If desired, the racemates obtained by any of the methods (A-K) may be resolved into their optically active antipodes. When a pharmaceutically acceptable, non-toxic acid addition salt is desired, the compound formed is reacted with a suitable acid.

The method of preparation A is preferably performed in a high boiling, inert, organic solvent, such as l,2,3,4-tetrahydronaphthalene, decahydronaphthalene, benzonitrile, paraffin oil or chlorinated, aromatic organic solvents; alternatively, the reaction may be carried out in the molten state at a temperature of l50-220C., preferably l-200C.

The properties of the novel para-substituted phenoxyhydroxypropylamines, particularly their selectivity in blocking the B-receptors of the heart, make them useful in treating heart diseases in animals including humans. In clinical practice the compounds of the present invention will normally be administered orally, rectally or by injection, in the form of pharmaceutical preparations comprising as the active ingredient at least one of the compounds encompassed by Formula IV as defined herein. The active ingredients may be used either as a free base or as a pharmaceutically acceptable non-toxic, acid addition salt, for example, the hydrochloride, lactate, acetate, sulfamate, and the like, in association with a pharmaceutically acceptable carrier. Accordingly, terms relating to the novel compounds of this invention whether generically or specifically are intended to include both the free amine base and the acid additionn salts of the free base, unless the context in which such terms are used, particularly in the examples, would be inconsistent with the broad concept. The carrier may be a solid, semi-solid or liquid diluent or capsule.

The pharmaceutical preparations are a further aspect of this invention. Usually the active substance will constitute between 0.1 and by weight of the preparation, more specifically between 0.5 and 20% by weight for preparation intended for injection and between 0.2 and 50% by weight for preparations suitable for oral administration.

To produce pharmaceutical preparations containing a compound of the invention in the form of dosage units for oral application, the selected compound may be mixed with a solid pulverulent carrier, for example, lactose, saccharose, sorbitol, mannitol, starches such as potato starch, corn starch or amylopectin, cellulose derivatives, or gelatin, and a lubricant such as magnesium stearate, calcium stearate, polyethylene glycol waxes, and the like, and then compressed to form tablets. If coated tablets are required, the cores, prepared as described above, may be coated with a concentrated sugar solution which may contain, for example, gum arabic, gelatin, talcum, titanium dioxide, and the like. Alternatively, the tablet can be coated with a lacquer dissolved in a readily volatile organic solvent or mixture of organic solvents. Dyestuffs may be added to these coatings in order to readily distinguish between tablets containing different active substances or different amounts of the active compound.

For the preparation of soft gelatin capsules (pearlshaped closed capsules) consisting of gelatin and, for example, glycerol or similar closed capsules, the active substance may be admixed with a vegetable oil. Hard gelatin capsules may contain granulates of the active substance in combination with solid, pulverulent carriers such as lactose, saccharose, sorbitol, mannitol, starches (e.g., potato starch, corn starch or amylopectin), cellulose derivatives or gelatin.

Dosage units for rectal application can be prepared in the form of suppositories comprising the active substance in admixture with a neutral fatty base, or gelatin rectal capsules comprising the active substance in admixture with vegetable oil or paraffin oil.

Liquid preparations for oral application may be in the form of syrups or suspensions, for example, solutions containing from about 0.2% to about 20% by weight of the active substance according to Formula IV, the balance being sugar and a mixture of ethanol, water, glycerol, and propylene glycol. Optionally, such liquid preparations may contain coloring agents, flavoring agents, saccharine and carboxymethylcellulose as a thickening agent.

Solutions for parenteral applications by injection can be prepared in an aqueous solution of a water-soluble pharmaceutically acceptable salt of the active substance preferably in a concentration of from about 0.5% to about 10% by weight. These solutions may also contain stabilizing agents and/or buffering agents and may conveniently be provided in various dosage unit ampoules.

The following examples illustrate the principles and practices of the invention and are not intended to limit its scope in any way. All percentages are by weight unless otherwise indicated.

EXAMPLE I 1,2-epoxy-3-[p-(B-methoxyethyl)-phenoxy]-propane (16.7 g) was dissolved in 50 ml isopropanol and mixed with ml isopropylamine. The mixture was heated in an autoclave on boiling water-bath overnight, whereafter it was evaporated and the remainder dissolved in 2 N HCl. The solution was extracted first with ether and thereafter with methylene chloride. After evaporating the methylene chloride phase, the hydrochloride of lisopropylaminio-3-[p-(B-methoxyethyl)-phenoxy]- propanol-2 was obtained which, after recrystallization from ethyl acetate, weighed 10.4 g. Melting point 83C. Equiv. weight: found 304.0, calculated 303.8. The starting material l,2-epoxy-3-[p-(B-methoxyethyl)- phenoxy]-propane was obtained from p-(B- methoxyethyl)-phenol which was reacted with epichlorohydrine whereafter the reaction product was distilled at l18-l28C. at a pressure of 0.35 mm Hg.

According to the method described in Example I, the following compounds were similarly prepared as hydrochlorides.

EXAMPLE ll l-isopropylamino-3-[p-(B-ethoxyethyU-phenoxy1- propanol-2. Melting point 102C. Equiv. weight: found 323.0, calculated 317.8.

EXAMPLE III 1-isopropylamino-3-(p-ethoxymethyl-phenoxy)- propanol-2. Melting point 94C. Equiv. weight: found 304.0, calculated 303.8.

EXAMPLE IV l-Tertiarybutylamino-3 p-( B-methoxyethyl phenoxy]-propanol-2 hydrochloride having the melting point 116C was prepared in accordance with Example I except that the isopropyl amine was replaced by the tert.-butyl amine. Equivalent weight: found 319, calculated 318.

EXAMPLE V 1-lsopropylamino-3-[p-(B-methylmercaptoethyl)- phenoxy]-propanol-2 in base form was prepared in accordance with Example I with the exception that no reaction with hydrochloric acid took place. Melting point 60C. Equivalent weight: found 284, calculated 283.

EXAMPLE VI 7 l-lsopropylamino-3-[p-(y-methoxypropyhphenoxy]-propanol-2, melting point 89C (hydrochloride) was prepared. The starting material p-(ymethoxypropyl)-phenyl-glycidyl ether has ,a boiling point at l02-ll2C and 0.03 mm Hg. Equivalent weight: found 314.0, calculated 317.8.

EXAMPLE VII l-isopropylamino-3-[p-(B- methoxycarbonylamidoethyl)-phenoxy]-propanol-2. Melting point 106C. Equiv. weight: found 349, calculated 347.

EXAMPLE VIII 1 -isopropylamino-3- p-( ,B- ethoxycarbonylamidoethyl)-phenoxy]-propanol-2. Melting point C. Equiv. weight: found 364, calculated 361.

The para-substituted phenylglycidyl ethers used in Examples Il-Vlll were obtained from the corresponding phenols and epichlorohydrin according to Example I. These glycidyl ethers were used without isolation until the last step.

EXAMPLE 1X (Illustrating Method B) an autoclave on a water bath with boiling water for 10 hours. Thereafter the mixture was evaporated and the residue was shaken with a mixture of 2/N NaOH and ether. The ether phase was dried and evaporated at reduced pressure. The residue so obtained crystallized from petroleum ether and there was thus obtained 1- isopropylam ino-3-[ p-( B-m ethoxyethyl )-p henoxy propanol-2, which was converted to the hydrochloride in accordance with Example I. The melting point of the hydrochloride was 83C.

EXAMPLE X (Illustrating Method C) A solution of 20 g of p-(B-methoxyethyD-phenyl glycidyl ether in 200 ml of ethanol saturated with ammonia was heated in an autoclave on a water bath with boiling water for 4 hours. The mixture was thereupon evaporated and the residue was dissolved in ethyl acetate whereupon gaseous I-ICl was introduced into the solution. The hydrochloride of the amine, which then crystallized, was removed by filtration and 5 g was dissolved in 50 ml of methanol and 10 ml of acetone. The solution was cooled to C and g of sodium borohydride was added in portions during 1 hour. Then 2.5 ml of acetone and 0.8 g of sodium borohydride were added and the solution was kept at room temperature for 1 hour whereupon 150 ml of H 0 was added. The mixture was extracted with ether whereupon the ether phase was dried over potassium carbonate and evaporated. The residue was transformed to the hydrochloride by dissolving the base in ethyl acetate and introducing gaseous HCl into the solution. In this way the hydrochloride of l-isopropylamino-3-[p-(B- methoxy'ethyl)-phenoxy]-propanol-2 was obtained having a melting point of 83C.

EXAMPLE XI (Illustrating Method D) A solution of g of p-( B-ethoxyethyU-phenyl glycidyl ether in 100 ml of ethanol was saturated with ammonia whereupon the mixture was heated upon a water bath containing boiling water for 4 hours. Thereafter the reaction mixing was evaporated and the residue dissolved in ethyl acetate. I-ICl in gaseous form was introduced causing the amine hydrochloride to crystallize.

The crystals were removed by filtration and dissolved in 70 ml of ethanol whereupon 10 ml of isopropylbromide and 12 g of potassium carbonate was added. The mixture was heated in an autoclave at 120C for 10 hours whereupon the ethanol was removed by evaporation. To the residue was added 100 ml of 2/N I-ICl and 100 ml of ether. The water phase was separated and alkalized with 2/N NaOH and thereupon extracted with ethyl acetate. The ethyl acetate phase was dried by means of potassium carbonate whereupon gaseous I-ICI was introduced. This caused crystallization of the hydrochloride which was separated by filtration and recrystallized from methylethylketone. There was thus obtained the hydrochloride of l-isopropylamino-3-[p- (B-ethoxyethyD-phenoxy]-propanol-2 having a melting point of 102C.

EXAMPLE XII (Illustrating Method E) A solution of 8 g of 3-[p-(/3-ethoxyethyl)-phenoxy]- l-chloropropanol-2 (prepared for instance according to method B) in 15 ml of dihydropyran was mixed with a small amount of p-toluene sulphonic acid. This caused an increase of the temperature to 50C and after having been kept at this temperature for 30 minutes the mixture was dissolved in I00 ml of ethanol whereupon 10 ml of isopropylamine was added. The reaction was heated in an autoclave for 10 hours on steam bath and was thereafter evaporated. The residue was dissolved in ethyl acetate to which was added oxalic acid and was thereupon diluted with ether. The crystallized oxalate was separated and recrystallized from ethanol/ether. To the oxalate was added 50 ml of 2/N HCl and the mixture was heated on water bath for 15 minutes. After cooling the mixture was alkalized by addition of NaOH and the base was extracted with ether. The ether phase was dried and evaporated whereafter the residue was dissolved in ethyl acetate followed by introduction of gaseous BC]. The precipitate thus obtained was recrystallized from methylethylketone which gave the hydrochloride of lisopropylamine-3-[p-(B-ethoxyethyl)-phenoxy]- 1 propanol-2 having a melting point of 103C.

EXAMPLE XIII (Illustrating Method F) 5.5 g of 3-isopropyl-5-[p-(B-methoxyethyhphenoxymethyl]-oxazolidinone-2 was dissolved in 60 ml of ethanol to which was added a solution of 9 g of KOH in 15 ml of H 0. The mixture was refluxed, was thereupon evaporated and the residue dissolved in 2/N I-ICI and extracted with ether. The water phase was alkalized with NaOH and extracted with ether. After drying by means of potassium carbonate, gaseous BC] was introduced, causing the hydrochloride of lisopropylamino-3 p-( B-methoxyethyl )-phenoxy propanol-2 to crystallize. The hydrochloride gave after recrystallization from methylethyl ketone, a melting point of 83C.

EXAMPLE XIV (Illustrating Method A and G) 4.5 g of p-(B-ethoxyethyl)-phenyl glycidyl ether was dissolved in 50 ml of tetralin to which was added 5.7 g of N,N'-diisopropylurea and 20 g of lithium hydroxide whereupon the mixture was heated at 200C for 3 hours. The reaction mixture was after cooling diluted with 50 ml of ether and shaken with ml of 2/N I-ICl. The water phase was extracted with ether and thereupon alkalized by addition of NaOH and was finally shaken with ether. The etherphase was washed with water, dried and evaporated. The residue was dissolved in ethyl acetate and the hydrochloride precipitated by addition of a solution of gaseous l-ICl in ether. The hydrochloride of 1-isopropylamino-3-[p-(B-ethoxyethyl)- phenoxy]-propanol-2 with a melting point of 102C was obtained after recrystallization from methylethyl ketone.

EXAMPLE XV (Illustrating Method H and l) 0.92 g of Na was dissolved in 50 ml of alcohol and to the solution was added 6.1 g of p-(B-methoxyethyD- phenol 9.6 g of 3-(N-benzyl-N-isopropylamino)-lchloropropanol-2. The mixture was heated in an autoclave on steam bath overnight and was thereupon filtered and evaporated to dryness. To the residue was added 100 ml of 2/N I-ICl and the mixture was extracted with ether whereupon the water phase was alkalized by addition of NaOH and thereupon shaken with ether. The ether phase was dried and evaporated and the residue obtained dissolved in 200 ml of alcohol and neutralized with concentrated HCl. To this solution was added 0.5 g of Pd/C catalyst and the reaction mixture was hydrogenated at atmospheric pressure until the calculated amount of H had been consumed. After filtering, the reaction mixture was evaporated to dryness and the residue thereupon recrystallized from methylethylketone giving the hydrochloride of lisopropylamino-3-[p-( B-methoxyethyl )-phenoxy]- propanol-2, having a melting point of 83C.

EXAMPLE XVI (Illustrating Method J) 15.2 g of p-(B-methoxethyD-phenol was dissolved in a solution of 4.6 g of Na in 100 ml of ethanol. To the solution was added 12.5 g of 2-hydroxy-3- chloropropionic acid and the mixture was refluxed for 3 hours. The mixture was thereupon evaporated and to the residue was added 100 ml of 2/N HCl and the resulting mixture was thereupon extracted with benzene. The benzene phase was shaken with sodium bicarbonate solution which was thereupon acidified by addition of HCl followed by an extraction with benzene. After evaporation 2-hydroxy-3-[p-(methoxyethyl)-phenoxy]-propionic acid was obtained which was converted to N-isopropylamide by dissolving the acid in tetrahydrofuran followed by an addition of isopropylamine and dicyclohexyl-dicarbodiimide and heating the reaction mixture at 40C for 5 hours. To the solution, after filtering, was added 5 g of lithium aluminum hydride and the mixture was refluxed overnight. After the application of conventional separation methods, 1- isopropylamino-3-[p-(fi-methoxyethyl)-phenoxy]- propanol-Z was obtained, which, after conversion to the hydrochloride, had a melting point of 82C.

EXAMPLE XVII (Illustrating Method K) To 5 g of N-isopropyl-N-[3-[p-(B-methoxyethyl)- phenoxy]-2-hydroxypropyl] carbamic acid-ethyl ester was added ml of 2/N I-ICl and the mixture was heated on water bath for 2 hours. After cooling, the mixture was extracted with ether and the water phase was alkalized by addition of NaOl-I, followed by an extraction with ether. After drying and evaporation and recrystallization from petroleum ether, 1- isopropylamino-3- p-( B-m ethoxyethyl )-phenoxy]- propanol-2 was obtained having a melting point of 83C, (hydrochloride).

EXAMPLE VIII (Method other than A- K) 1-Isopropylamino-3-[p-( y-aminopropyl)-phenoxy]- propanol-Z-di-HCI (3.4 g) was dissolved in 15 ml H O. Sodium bicarbonate (2.6 g) was added to the solution and after a few minutes while stirring, 1.0 g of methyl chloroformate' was added. The mixture was stirred overnight at room temperature, followed by extraction with methylenee dichloride. The methylene dichloride phase was dried with K CO filtered and evaporated. In this way the base form of 1-isopropylamino-3-[p-('ymethoxycarbonylamidopropyl )-phenoxy ]-propanol-2- was obtained (m.p.=72C). Equivalent weight: Found 329; Calculated 324.

The starting material, l-isopropylamino-3-[p-(yaminopropyl)phenoxy]-propanol-2, was prepared in the following manner: p-(B-cyanoethyDphenol (100.9 g), 149.1 g epichlorohydrin, 226 g K CO and 700 ml acetonitrile were mixed and refluxed while stirring overnight.

After filtration, the filtrate was evaporated in vacuo. The residue (1 15 g) was dissolved in 300 ml of isopropanol; 300 ml of isopropylamine was added, whereupon the mixture was refluxed for 3 hours. After evaporation in vacuo 138.5 g of an oil was obtained. 8.5 g of this oil was dissolved in 500 ml of ethanol (99%) and 8.5 ml of cone. I-ICl was added, followed by hydrogenation at 3.5 atm. (0.5 g. Pd/C as a catalyzing agent) until the calculated amount of hydrogen was consumed. After filtration, evaporation and recrystallization from alcohol, the dihydrochloride of l-isopropylamino-3-[p- (y-aminopropyD-phenoxy]-propanol-2 (mp. 180C) was obtained.

EXAMPLE XIX According to the method described in Example XVIII the compound l-tert.-butylamino-3[p-(B- methoxycarbonylamidoethyl)-phenoxy]-propanol-2 was prepared (m.p.=92C in base form; Equivalent weight: found 325; calculated 324). The compound 1- tert.-butylamino-3-[p-(B-aminoethyl)-phenoxy]- propanol-2-di-l-IC1 (m.p.=l92C) was used as starting material. This latter compound was prepared according to the method described in Example XVIII using pcyanomethylphenol and tert.-butylamine as starting materials.

PHARMACOLOGICAL EVALUATION Compounds prepared according to the examples were evaluated for intrinsic activity and blocking effect on heart rate and peripheral vasodilator response to isoprenaline in the cat. The acute LD in mice was evaluated. Alprenolol was used as a reference substance.

Cats weighing between 1.8 and 2.8 kg were anaesthetized with 30 mg/kg pentobarbital sodium, intraperitoneally. The cats had been pretreated with reserpine, 5 mg/kg intramuscular, about 18 hours before the experiment. Bilateral vagotomy was performed before the start of the experiment.

The heart rate was recorded on an Offner cardiotachometer triggered by the EKG-complex. Mean arterial blood pressure was recorded from a carotid artery. The peripheral resistance was measured in one of the legs of the cat in the following way: The femoral artery was opened in the inguinal region and the leg was perfused by blood delivered through a sigma motor pump at con stant rate. The flow resistance (the pressure) was recorded via a pressure transducer connected to the catheter distally to the pump. The paw was excluded frorr the circulation by a tight ligature. Intravenously injected isoprenaline increased the heart rate and re duced the perfusion pressure. An isoprenaline dose giving -80% of the maximal chronotropic response was determined. This dose (usually 0.1 ag/kg) was then repeated with 20 minute intervals. Ten minutes bGfOl'E each isoprenaline injection, the tested substances were administered intravenously for 2 minutes, starting witt a dose of 0.01 mg/kg and increasing each subsequen (XVI-II) s/ (ciH z TABLE I heart than of the receptors in smooth muscles. Due to this cardioselectivity, the compounds according to the invention give therapeutic effects in treating cardiovascular diseases without risk or complications due to B-blockade in bronchi and blood vessels.

The following examples illustrate methods of preparing some pharmaceutical preparations according to the invention.

EXAMPLE XX A syrup containing 2% (weight per volume) of active substance according to the invention was produced from the following ingredients:

l-isopropylamino-3-(p-methoxyethyl-phenoxy) propanol-Z [HCl] Saccharin Sugar 3 Glycerol Flavoring agent Ethanol (96%) Distilled water (balance) 99 o-oooo gnemanarmaa l l to IO0.0 ml

The sugar, saccharin and the ether salt werer dissolved in grams of hot water. After cooling, the glyc- Compounds Tested Reserpinized eat Mouse Intrinsic b1o ade B-blockactivity Heart rate 'ade 2 n of a m E13 mg/kgperinheral LD5O lsoprenalgtne vascular i.p. (except allyl) heart rate re ista e "lg/k o-al1yl (alprenolol) 20 l 0.1 0.05

CH 0CH CH (Ex. I) 0 0. 3 200 C H OCH CH -(Ex II) 0 0.3 i

C H OCH -(Ex. III) 0 0. l 6

CH OQ-NHCH CH (Ex.VII) 0 0. l 19 125 C H 0E-NHCH CH O O. 3 25 200 (Ex.VIII) B-blocking activity for the test substances was 605 00 times lower than the activity of alprenolol. These results demonstrate that the test substances, developed a relatively stronger blockade of the B-receptors of the erol was added and a solution of the flavoring agent in ethanol was added. The mixture was then made up to a volume of 100 milliliters with water.

The active substance in this composition may be replaced by other pharmaceutically acceptable, nontoxic acid addition salts.

EXAMPLE XXI l-isopropylamino-3-(p-ethoxyethylphenoxy)- propano1-2 hydrochloride (250 g) was mixed with lactose (175.8 g), potato starch (169.7 g) and colloidal silica (32 g). The mixture was moistened with a gelatin solutionand granulated through a 12 mesh sieve. After drying, potato starch (160 g), talc (50 g) and magnesium stearate (2.5 g) were mixed in and the resulting mixture was pressed into tablets (10,000) containing 25 milligrams of active substance which were suitable for use as tablets. The tablets were marked with break lines to enable a dose other than 25 milligrams or multiples thereof tobe administered.

EXAMPLE XXIl A granulate was prepared from l-isopropylamino-3- (ethoxym ethyl-phenoxy )-propanol-2 hydrochloride (250 g), lactose (175.9 g) and an alcoholic solution of polyvinyl pyrrolidone (25 g). After drying, the granulate was mixed with talc (25 g), potato starch (40 g) and magnesium stearate (2.50 g) and pressed into 10,000 biconvex tablets. These tablets were first coated with a 10% alcoholic shellac solution and then with a water solution containing saccharose (45%), gum arabic (5%) gelatin, (4%) and dyestuff (0.2%). Talc and sugar powder were used as dusting powders after the first 15 applications. The coating was then finished with a 66% sugar syrup and polished with a 10% carnauba wax solution in carbon tetrachloride.

EXAMPLE XXIII l-isopropylamino-3-(p-methoxyethylphenoxy)- propanol-2-hydrochloride (1 g), sodium chloride (0.8 g) and ascorbic acid (0.1 g) were dissolved in sufficient distilled water to make 100 milliliters of solution. This solution, each milliliter of which contained 10 milligrams of the active substance, was used to fill ampoules which were sterilized by heating for minutes at 120C.

Many obvious variations of the invention disclosed will suggest themselves to those skilled in the art. Nothing in the preceding specification is intended, however, to limit the scope of the invention as defined by the following claims.

We claim:

I. A pharmaceutical preparation for treatment of cardiovascular diseases which comprises as an active ingredient a therapeutically effective .dose of at least one para-substituted phenoxy-hydroxypropylamine compound selected from the group consisting of compounds having the formula (CH Z and pharmaceutically acceptable, non-toxic acid addition salts thereof, wherein R is an isopropyl or tertiarybutyl radical; Z is a member selected from the group consisting of OR, and -SR", R" being a straight or branched alkyl radical having 1 to 3 carbon atoms and n is l, 2 or 3, in association with a pharmaceutically acceptable carrier.

2. A pharmaceutical preparation according to claim 1 wherein the active ingredient is a therapeutically effective dose of at least one said compound in racemic form.

3. A pharmaceutical preparation according to claim 1 wherein the active ingredient is a therapeutically effective dose of at least one said compound as the optically active, dextro-rotatary isomer.

4. A pharmaceutical preparation according to claim 1 wherein the active ingredient is a therapeutically effective dose of at least one said compound as the optically active, levo-rotatary isomer.

5. A pharmaceutical preparation according to claim 1 wherein the para-substituted phenoxyhydroxypropylamine compound comprises 0.1 to by weight of the preparation.

6. A pharmaceutical preparation according to claim 1 in a form suitable for administration by injection wherein the para-substituted phenoxyhydroxypropylamine compound comprises about 0.5% to about 20% by weight of the preparation.

7. A pharmaceutical preparation according to claim 6 for parenteral application which comprises an aqueous solution of a water soluble salt of said parasubstituted phenoxy-hydroxypropylamine compound in an amount of about 05-10% by weight of the preparation.

8. A pharmaceutical preparation according to claim 1 in a form suitable for oral administration wherein the para-substituted phenoxy-hydroxypropylamine compound comprises about 0.2% to about 50% by weight of the preparation.

9. A pharmaceutical preparation according to claim 1 wherein the active ingredient is l-isopropylamino-3- [p-(B-methoxyethyl)-phenoxy]-propanol-2 or a pharmaceutically acceptable non-toxic addition salt thereof.

10. A pharmaceutical preparation according to claim 1 wherein the active ingredient is l-isopropylamino-3- [p-(B-ethoxyethyl)-phenoxy]-propanol-2 or a pharmaceutically acceptable non-toxic addition salt thereof.

1 l. A pharmaceutical preparation according to claim 1 wherein the active ingredient is l-isopropylamino-3- (p-ethoxymethyl-phenoxy)-propanol-2 or a pharmaceutically acceptable non-toxic addition salt thereof.

12. A pharmaceutical preparation wherein the active propyl in association with a pharmaceutically acceptable carrier.

13. A pharmaceutical preparation wherein the active ingredient is the compound of claim 1 wherein Z is -OR" in association with a pharmaceutically acceptable carrier.

14. A pharmaceutical preparation wherein the active ingredient is the compound of claim 1 wherein Z is -SR" in association with a pharmaceutically acceptable carrier.

15. A pharmaceutical preparation wherein the active ingredient is the compound of claim 1 wherein R is tertiary butyl in association with a pharmaceutically acceptable carrier.

16. A method for treating cardiovascular diseases in animals including humans which comprises adminstering a therapeutically effective dose of a parasubstituted phenoxyhydroxypropylamine compound selected from the group consisting essentially of compounds having the formula (CH Z and pharmaceutically acceptable, non-toxic acid addition salts thereof, wherein R is an isopropy] or tertiarybutyl radical; Z is a member selected from the group consisting of OR", and -SR", R being a straight or branched alkyl radical having 1 to 3 carbon atoms:

19. A method according to claim 16 wherein the phenoxyhydroxypropylamine compound is lisopropylamino-3-(p-ethoxymethyl-phenoxy propanol-Z.

20. A method for treating cardiovascular diseases in animals includinghumans which comprises adminstering a therapeutically effective dose of a parasubstituted phenoxyhydroxypropylamine compound according to claim 16 wherein R is isopropyl.

21. A method for treating cardiovascular diseases in animals including humans which comprises administering a therapeutically effective dose of a parasubstituted phenoxyhydroxypropylamine compound according torclaim 16 wherein Z is OR".

22. A method for treating cardiovascular diseases in animals including humans which comprises administering a therapeutically effective dose of a parasubstituted phenoxyhydroxypropylamine compound according to claim 16 wherein Z is SR".

23. A method for treating cardiovascular diseases in animals including humans which comprises administering a therapeutically effective dose of a parasubstituted phenoxyhydroxypropylamine compound according to claim 16 wherein R is tertiary butyl.

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION PATENT NO. 1 3 87 02 DATED :April 8, 1975 INVENTOR(S) Brandstrom et al It is certified that error appears in the above-identified patent and that said Letters Patent are hereby corrected as shown below:

Front page, insert the following Item after Item [60] z [30] Foreign Application Priority Data Feb. 18, 1970 Sweden 2050/70--;

Front page, Item [60] after "March 19 1973" delete "abandoned" and insert Pat. No. 3,873,600.

Signed and Sealed this [SEAL] I Twenty-first D f September 1976 A nest.

RUTH C. MASON Artesting Officer 

1. A PHARMACEUTICAL PREPARATION FOR TREATMENT OF CARDIOVASCULAR DISEASES WHICH COMPRISES AS AN ACTIVE INGREDIENT A THERAPEUTICALLY EFFECTIVE DOSE OF AT LEAST ONE PARA-SUBSTITUTED PHENOXY-HYDROXYPROPYLAMINE COMPOUND SELECTED FROM THE GROUP CONSISTING OF COMPOUNDS HAVING THE FORMULA
 2. A pharmaceutical preparation according to claim 1 wherein the active ingredient is a therapeutically effective dose of at least one said compound in racemic form.
 3. A pharmaceutical preparation according to claim 1 wherein the active ingredient is a therapeutically effective dose of at least one said compound as the optically active, dextro-rotatary isomer.
 4. A pharmaceutical preparation according to claim 1 wherein the active ingredient is a therapeutically effective dose of at least one said compound as the optically active, levo-rotatary isomer.
 5. A pharmaceutical preparation according to claim 1 wherein the para-substituted phenoxy-hydroxypropylamine compound comprises 0.1 to 95% by weight of the preparation.
 6. A pharmaceutical preparation according to claim 1 in a form suitable for administration by injection wherein the para-substituted phenoxy-hydroxypropylamine compound comprises about 0.5% to about 20% by weight of the preparation.
 7. A pharmaceutical preparation according to claim 6 for parenteral application which comprises an aqueous solution of a water soluble salt of said para-substituted phenoxy-hydroxypropylamine compound in an amount of about 0.5-10% by weight of the preparation.
 8. A pharmaceutical preparation according to claim 1 in a form suitable for oral administration wherein the para-substituted phenoxy-hydroxypropylamine compound comprises about 0.2% to about 50% by weight of the preparation.
 9. A pharmaceutical preparation according to claim 1 wherein the active ingredient is 1-isopropylamino-3- p-(.beta.-methoxyethyl)-phenoxy!-propanol-2 or a pharmaceutically acceptable non-toxic addition salt thereof.
 10. A pharmaceutical preparation according to claim 1 wherein the active ingredient is 1-isopropylamino-3- p-(.beta.-ethoxyethyl)-phenoxy!-propanol-2 or a pharmaceutically acceptable non-toxic addition salt thereof.
 11. A pharmaceutical preparation according to claim 1 wherein the active ingredient is 1-isopropylamino-3-(p-ethoxymethyl-phenoxy)-propanol-2 or a pharmaceutically acceptable non-toxic addition salt thereof.
 12. A pharmaceutical preparation wherein the active ingredient is the compound of claim 1 wherein R'' is isopropyl in association with a pharmaceutically acceptable carrier.
 13. A pharmaceutical preparation wherein the active ingredient is the compound of claim 1 wherein Z is --OR" in association with a pharmaceutically acceptable carrier.
 14. A pharmaceutical preparation wherein the active ingredient is the compound of claim 1 wherein Z is --SR" in association with a pharmaceutically acceptable carrier.
 15. A pharmaceutical preparation wherein the active ingredient is the compound of claim 1 wherein R'' is tertiary butyl in association with a pharmaceutically acceptable carrier.
 16. A method for treating cardiovascular diseases in animals including humans which comprises adminstering a therapeutically effective dose of a para-substituted phenoxyhydroxypropylamine compound selected from the group consisting essentially of compounds having the formula
 17. A method according to claim 16 wherein the phenoxyhydroxypropylamine compound is 1-isopropylamino-3- p-(.beta.-methoxyethyl)-phenoxy!-propanol-2.
 18. A method according to claim 16 wherein the phenoxyhydroxypropylamine compound is 1-isopropylamino-3- p-(.beta.-ethoxyethyl)-phenoxy!-propanol-2.
 19. A method according to claim 16 wherein the phenoxyhydroxypropylamine compound is 1-isopropylamino-3-(p-ethoxymethyl-phenoxy)-propanol-2.
 20. A method for treating cardiovascular diseases in animals including humans which comprises adminstering a therapeutically effective dose of a para-substituted phenoxyhydroxypropylamine compound according to claim 16 wherein R'' is isopropyl.
 21. A method for treating cardiovascular diseases in animals including humans which comprises administering a therapeutically effective dose of a para-substituted phenoxyhydroxypropylamine compound according to claim 16 wherein Z is --OR".
 22. A method for treating cardiovascular diseases in animals including humans which comprises administering a therapeutically effective dose of a para-substituted phenoxyhydroxypropylamine compound according to claim 16 wherein Z is --SR".
 23. A method for treating cardiovascular diseases in animals including humans which comprises administering a therapeutically effective dose of a para-substituted phenoxyhydroxypropylamine compound according to claim 16 wherein R'' is tertiary butyl. 